1. First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia. Issue 3 (16th January 2023) Authors: Boyiadzis, Michael; Desai, Pinkal; Daskalakis, Nikki; Donnellan, William; Ferrante, Lucille; Goldberg, Jenna D.; Grunwald, Michael R.; Guttke, Christina; Li, Xiang; Perez‐Simon, Jose Antonio; Salamero, Olga; Tucker, Trevor; Xu, Xiaoying; Yang, Jay; Pemmaraju, Naveen; Alonso‐Dominguez, Juan Manuel Journal: Clinical and translational science Issue: Volume 16:Issue 3(2023) Page Start: 429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Issue 7 (July 2019) Authors: Soumerai, Jacob D; Ni, Ai; Darif, Mohamed; Londhe, Anil; Xing, Guan; Mun, Yong; Kay, Neil E; Shanafelt, Tait D; Rabe, Kari G; Byrd, John C; Chanan-Khan, Asher A; Furman, Richard R; Hillmen, Peter; Jones, Jeffrey; Seymour, John F; Sharman, Jeffrey P; Ferrante, Lucille; Mobasher, Mehrdad; Stark, Th... Journal: Lancet Issue: Volume 6:Issue 7(2019) Page Start: e366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. (June 2019) Authors: Martin, Peter; Goy, Andre; Ramchandren, Radhakrishnan; Ferrante, Lucille; Londhe, Anil; McGowan, Tracy; Bartlett, Nancy L Journal: Journal of oncology pharmacy practice Issue: Volume 25:Number 4(2019) Page Start: 1027 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗